Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab vs Rituximab in Pediatric Nephrotic Syndrome
NCT02394119Phase 2Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ofatumumab in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Istituto Giannina Gaslini. Primary endpoint: Risk of relapse at 12 months. Started Jun 2015; status: completed.
02
Drugs
ofatumumab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT02394119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394119.